Granules India Completes Acquisition of Senn Chemicals
ECONOMY & POLICY

Granules India Completes Acquisition of Senn Chemicals

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. 

The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. 

Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. 

Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. 

The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. 

Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). 

This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. 


(BSE)     

Granules India Ltd. has officially closed the acquisition of Senn Chemicals AG, a Switzerland-based CDMO specialising in peptide development and manufacturing. This strategic move marks Granules’ entry into the peptide therapeutics segment and contract development and manufacturing (CDMO) services, bolstering its innovation-led growth strategy. The acquisition, executed through Granules’ wholly owned subsidiary Granules Peptides Pvt. Ltd., involves a 100% equity stake purchase from the founding Senn family. Headquartered in Dielsdorf, Switzerland, Senn Chemicals brings over six decades of expertise in Liquid-Phase and Solid-Phase Peptide Synthesis (LPPS & SPPS), serving pharmaceutical, cosmetic, amino acid derivative (AAD), and theragnostic markets. Dr. Krishna Prasad Chigurupati, Chairman and MD of Granules India, highlighted the deal as a “pivotal step” in the company’s evolution into a science- and innovation-led enterprise. He emphasised the synergy between Senn’s peptide specialisation and Granules’ global manufacturing capabilities to drive high-quality, next-gen treatments in areas such as GLP-1 receptor agonists, anti-diabetic, and anti-obesity therapies. The acquisition also marks Granules’ formal entry into the CDMO sector, enhancing its global footprint with access to regulated markets, top-tier European scientific talent, and advanced R&D capabilities. Joint development initiatives in peptide APIs are already underway, with an expanded pipeline in the works. Advisors on the deal included Stifel Nicolaus India (financial), Loyens & Loeff (legal), Deloitte (financial and tax diligence), and Kroll (valuation). This acquisition strengthens Granules’ innovation capabilities and positions it as a key player in the rapidly growing complex therapeutics and CDMO markets. (BSE)     

Next Story
Infrastructure Transport

Mumbai-Ahmedabad Bullet Train Set to Launch by 2028

India’s first bullet train is set to revolutionize high-speed travel along the western corridor, with the Mumbai-Ahmedabad high-speed rail project aiming for a 2028 launch. This announcement marks a major milestone in India’s infrastructure goals, as it promises to reduce travel time between the two economic hubs from eight hours to just three.Spanning a planned 508-kilometre stretch, the corridor stands as a flagship example of Indo-Japanese collaboration in technology and engineering. Once operational, the train is expected to transform intercity mobility and place India among the select..

Next Story
Infrastructure Transport

Mumbai-Gandhinagar Train Service Enhances Passenger Capacity

The Mumbai Central–Gandhinagar Capital Vande Bharat Express has increased its passenger capacity by adding four additional AC chair car coaches to meet the growing commuter demand on one of India’s busiest business corridors. This upgrade, effective from 11 May, raised the train’s seating capacity from 1,128 to 1,440 passengers, allowing it to serve 936 more passengers daily in both directions. The increase was described as a practical measure to accommodate the surging demand on the busy Mumbai–Ahmedabad–Gandhinagar route, which regularly operates at over 150 percent seat occupancy...

Next Story
Infrastructure Urban

Delhi Plans 12 Sewage Plants to Clean Najafgarh Drain Efficiently

Delhi’s ambitious plan to improve the water quality of the Yamuna River has gained significant momentum as the Delhi Jal Board (DJB) has begun work on 12 new sewage treatment plants (STPs) aimed at reducing the volume of untreated sewage being discharged from the Najafgarh Drain.This initiative forms part of the ongoing efforts to clean the Yamuna and restore the river’s health, which has long been a critical environmental issue for the national capital. Given the alarming pollution levels in the Yamuna, experts and officials consider this project a vital step toward addressing the persist..

Advertisement

Advertisement

Subscribe to Our Newsletter

Get daily newsletters around different themes from Construction world.

STAY CONNECTED

Advertisement

Advertisement

Advertisement

Advertisement

Talk to us?